Log in to search using one of your social media accounts:

 

Study ranks safety, effectiveness of cognitive enhancers for Alzheimer's
(St. Michael's Hospital) A new study ranking the safety and effectiveness of four drugs taken to enhance concentration, memory, alertness and moods, found that donepezil was most likely to effectively improve cognition in patients with Alzheimer's disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 29, 2017 Category: International Medicine & Public Health Source Type: news

Corium touts clinical data for transdermal delivery of Alzheimer ’s drug
Corium (NSDQ:CORI) touted data today from a pilot bioequivalence study, comparing its Corplex Donepezil transdermal patch to oral Aricept as delivery method for the most commonly prescribed treatment for Alzheimer’s disease. Data from the pilot study demonstrated that Corium’s transdermal patch met the criteria for bioequivalence to oral Aricept, as measured by primary pharmacokinetic endpoints previously established by the FDA. Get the full story at our sister site, Drug Delivery Business News. The post Corium touts clinical data for transdermal delivery of Alzheimer’s drug appeared first on MassDev...
Source: Mass Device - July 18, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Neurological Pharmaceuticals Wall Street Beat Corium Source Type: news

Namzaric (Memantine Hydrochloride Extended-release and Donepezil Hydrochloride Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 5, 2017 Category: Drugs & Pharmacology Source Type: news

Corium ’s Corplex Donepezil demonstrates positive outcome in pilot BE trial
US-based Corium International has reported positive preliminary results from a pilot bioequivalence (BE) clinical trial of Corplex Donepezil in healthy subjects. (Source: Drug Development Technology)
Source: Drug Development Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news

Dangerous Alzheimer's treatment drug DONEPEZIL being widely prescribed "off-label" was never approved for such uses by the FDA
(Natural News) Donepezil is an acetylcholinesterase inhibitor approved by the Food and Drug Administration (FDA) in the United States to treat Alzheimer’s disease. Since mild cognitive impairment (MCI), or the phase between normal age-related brain decline and dementia, displays similar symptoms to Alzheimer’s, many physicians also prescribe this drug off-label to patients with MCI. Researchers... (Source: NaturalNews.com)
Source: NaturalNews.com - May 2, 2017 Category: Consumer Health News Source Type: news

Study: Gene Test Needed Before Using Alzheimer's Drug'Off-Label '
Aricept is often prescribed for mild mental impairment without actual approval Source: HealthDay Related MedlinePlus Page: Alzheimer's Disease (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 7, 2017 Category: Consumer Health News Source Type: news

Study: Gene Test Needed Before Using Alzheimer's Drug'Off-Label '
TUESDAY, March 7, 2017 -- A drug used to treat Alzheimer's disease should not be prescribed to people with milder mental impairment without first giving them a genetic test, a new study urges. The drug is donepezil (brand name: Aricept). Donepezil... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 7, 2017 Category: Journals (General) Source Type: news

Alzheimer's drug prescribed off-label could pose risk for some
Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation - the K-variant of butyrylcholinesterase, or BChE-K - donezpezil could accelerate cognitive decline. (Source: World Pharma News)
Source: World Pharma News - February 27, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Alzheimer's drug prescribed off-label could pose risk for some
Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment without a genetic test. Researchers discovered that for people who carry a specific genetic variation -- the K-variant of butyrylcholinesterase, or BChE-K -- donezpezil could accelerate cognitive decline. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 26, 2017 Category: Science Source Type: news

Alzheimer's drug prescribed off-label could pose risk for some
(University of California - Los Angeles Health Sciences) Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation -- the K-variant of butyrylcholinesterase, or BChE-K -- donezpezil could accelerate cognitive decline. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 24, 2017 Category: Global & Universal Source Type: news

Alzheimer ’s drug prescribed ‘off-label’ for mild cognitive impairment could pose risk for some
FINDINGSDonepezil, a medication that is approved to treat people with Alzheimer ’s disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation — the K-variant of butyrylcholinesterase, or BChE-K — donezpezil could accelerate cognitiv e decline.BACKGROUNDMild cognitive impairment is a transitional state between normal age-related changes in cognition and dementia.  Because many people with the condition display symptoms similar to those caused by Alzheimer’...
Source: UCLA Newsroom: Health Sciences - February 23, 2017 Category: Universities & Medical Training Source Type: news

Among antidementia drugs, memantine is associated with the highest risk of pneumonia
A recent study from the University of Eastern Finland shows that among users of antidementia drugs, persons using memantine have the highest risk of pneumonia. The use of rivastigmine patches is associated with an increased risk as well. The study found that persons using donepezil or galantamine had the lowest risk of pneumonia. (Source: World Pharma News)
Source: World Pharma News - November 25, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Another Failure In Search For Treatment To Slow Alzheimer ’ s
INDIANAPOLIS (AP) — An experimental treatment for Alzheimer’s failed again in a widely anticipated study, disappointing many who had hoped Eli Lilly had finally found a way to slow the progression of the mind-robbing disease. The drug did not work better than a placebo treatment in a study of 2,100 people with mild Alzheimer’s, the company announced Wednesday. “We’re incredibly saddened by the news,” said Maria Carrillo, chief science officer of the Alzheimer’s Association, who was not involved in Lilly’s research. “There was a lot of hope for this avenue, this approach...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 23, 2016 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Alzheimer's Disease Solanezumab Source Type: news

Aricept (Donepezil Hydrochloride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 6, 2016 Category: Drugs & Pharmacology Source Type: news

Treatment of Alzheimer ’ s Disease
There is no cure for Alzheimer’s disease and no way to slow the progression of the disease. For some people in the early or middle stages of Alzheimer’s disease, medication such as tacrine (Cognex) may alleviate some cognitive symptoms. Donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl) may keep some symptoms from becoming worse for a limited time. A fifth drug, memantine (Namenda), has also been approved for use in the United States. Combining memantine with other Alzheimer’s disease drugs may be more effective than any single therapy. One controlled clinical trial found that patients...
Source: Psych Central - August 17, 2016 Category: Psychiatry Authors: Jane Framingham, Ph.D. Tags: Alzheimer's Medications Memory and Perception Alzheimer's treatment Cognex donepezil Drug Exelon galanta Namenda Reminyl rivastigmine tacrine treatment of alzheimers Source Type: news

donepezil, Aricept, Aricept ODT
Title: donepezil, Aricept, Aricept ODT Category: Medications Created: 5/31/1998 12:00:00 AM Last Editorial Review: 7/29/2016 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - July 29, 2016 Category: Geriatrics Source Type: news

Clinical Trials For New Alzheimer's Medication
Inside Science News Servicenoted on April 16, 2016 that "Alzheimer's is a graveyard for expensive drug tests. One study showed that between 2000 and 2012, 244 compounds were tested in 413 clinical trials. Only one was approved for use, a failure rate of 99.6 percent." The one medication that was approved since the year 2000, Namzeric, is a medication that combines two previously FDA-approved medications, donepezil and memantine, into one capsule. But neither donepezil nor memantine are medications that effectively treat or significantly improve the lives of most people who take them. Even the third sentence on ...
Source: Healthy Living - The Huffington Post - July 19, 2016 Category: Consumer Health News Source Type: news

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
This guidance updates and replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009). The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease has resulted in a change in the guidance. Specifically: donepezil, galantamine and rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer's disease, and memantine is now recommended as an option for managing moderate Alzheimer's disease for people who cannot take AChE inhibitors, and as an option for managing severe Alzhei...
Source: Current Awareness Service for Health (CASH) - July 12, 2016 Category: Consumer Health News Source Type: news

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
This guidance updates and replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009). The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease has resulted in a change in the guidance. Specifically: donepezil, galantamine and rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer's disease, and memantine is now recommended as an option for managing moderate Alzheimer's disease for people who cannot take AChE inhibitors, and as an option for managing severe Alzheimer'...
Source: Current Awareness Service for Health (CASH) - July 12, 2016 Category: Consumer Health News Source Type: news

Eisai wins approval to use Aricept for DLB treatment in Philippines
HI-Eisai Pharmaceutical, a subsidiary of Eisai in the Philippines, has obtained approval for a new indication Aricept (donepezil hydrochloride) to treat dementia with Lewy bodies (DLB). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 14, 2016 Category: Pharmaceuticals Source Type: news

Lupin launches generic Aricept tablets in US market
Lupin's product is a generic version of Eisai Inc's Aricept tablets which is indicated for the treatment of dementia of the Alzheimer's type. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 31, 2016 Category: Pharmaceuticals Source Type: news

Characteristics of pediatric exposures to antidementia drugs reported to a poison control system - Thornton SL, Pchelnikova JL, Cantrell FL.
OBJECTIVE: To characterize pediatric exposures to the antidementia drugs donepezil, memantine, rivastigmine, and galantamine by reviewing a poison control system's database. STUDY DESIGN: A retrospective review of a statewide poison control system's databa... (Source: SafetyLit)
Source: SafetyLit - March 11, 2016 Category: Global & Universal Tags: Age: Infants and Children Source Type: news

Alzheimer's Symptomatic Drug Set to Test as Donepezil Combo
BARCELONA — RVT-101, a novel small molecule that increases acetylcholine release, is poised for what its developers say could be its pivotal trial for U.S. approval. (Source: Caring for the Ages)
Source: Caring for the Ages - December 23, 2015 Category: Health Management Authors: Michele G. Sullivan Source Type: news

Revived Alzheimer's Symptomatic Drug Set to Test as Donepezil Combo
BARCELONA — RVT-101, a novel small molecule that increases acetylcholine release, is poised for what its developers say could be its pivotal trial for U.S. approval. (Source: Caring for the Ages)
Source: Caring for the Ages - November 25, 2015 Category: Health Management Authors: Michele G. Sullivan Source Type: news

Lupin gets FDA nod for generic Aricept tablets
Lupin said it has received final approval from the US drug regulator to market generic Aricept tablets used for treatment of dementia. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 3, 2015 Category: Pharmaceuticals Source Type: news

Not stopping donepezil may delay nursing home admission for Alzheimer’s patients
Drug is usually discontinued as symptoms worsen due to a lack of perceived benefit and to reduce costs to NHSRelated items from OnMedicaGovernment launches major drive to tackle dementia One in three people born this year in UK will develop dementiaDementia and stroke funding remains too low, say expertsWhy don’t dementia strategies work?Right lifestyle can slow down dementia claim (Source: OnMedica Latest News)
Source: OnMedica Latest News - October 28, 2015 Category: UK Health Source Type: news

Cheap Alzheimer's drug 'may help keep people out of care homes'
Conclusion This randomised controlled trial assessed the impact of continuing or discontinuing the Alzheimer's drug donepezil on the chances of nursing home admission in people with moderate to severe Alzheimer's. The study examined discontinuing or continuing donepezil, either alone or in combination with memantine, or switching to memantine alone. Memantine is currently licensed for the treatment of moderate to severe Alzheimer's, while donepezil is only licensed for mild to moderate forms of the disease. In this trial, people had already been taking donepezil for three to six months or more. These drugs are only given...
Source: NHS News Feed - October 27, 2015 Category: Consumer Health News Tags: Medication Mental health Neurology Older people Source Type: news

Stopping donepezil ups risk of care home admission
Withdrawing a commonly-prescribed Alzheimer’s drug in the advanced stages of the disease doubles the risk of patients moving to a nursing home within a year, according to a UK study. (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - October 27, 2015 Category: Nursing Source Type: news

Six pence drug could keep Alzheimer's patients out of care homes
The drug donepezil helps late stage dementia patients to cope with everyday tasks like dressing and shopping (Source: Telegraph Health)
Source: Telegraph Health - October 27, 2015 Category: Consumer Health News Tags: Alzheimer's disease donepezil independent living dementia care homes Source Type: news

Investigational Drug Added to Donepezil Shows Promise in ADInvestigational Drug Added to Donepezil Shows Promise in AD
Adding 5-HT6 receptor antagonist RVT-101 to standard therapy with donepezil in adults with mild to moderate Alzheimer's disease resulted in improved cognition and function. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 24, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Donepezil Add-On Promising in Completer Analysis
(MedPage Today) -- Serotonin modulator slows but doesn't stop cognitive decline in phase II re-analysis. (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - July 22, 2015 Category: Psychiatry Source Type: news

Alzheimer's Society comment on potential new symptomatic therapy for Alzheimer's disease
Results from a clinical trial reported at the Alzheimer's Association International Conference 2015 today (Wednesday 22 July) have shown positive evidence in boosting the efficacy of donepezil, also known as Aricept, which is used in mild to moderate Alzheimer's disease to relieve some symptoms of the condition. (Source: Alzheimers Society)
Source: Alzheimers Society - July 22, 2015 Category: Geriatrics Source Type: news

Donepezil Helps Some Patients Treated With Brain IrradiationDonepezil Helps Some Patients Treated With Brain Irradiation
Phase 3 trial results suggest that donepezil improves some aspects of cognition in patients with brain tumors treated with brain irradiation. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 30, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Experts Weigh In On The Ethics Of Using Brain-Enhancing Drugs
By: Tanya Lewis Published: March 26, 2015 08:00am ET Boosting a person's smarts through drugs or electrical or magnetic stimulation of the brain is becoming an increasingly widespread practice. Now, bioethicists are weighing in, saying that while such cognitive enhancement is neither bad nor good, it deserves more research. In the past, "there have been many arguments that suggest one should take an ethical stance for or against cognitive enhancement" of healthy individuals, said Amy Gutmann, chairwoman of the Presidential Commission for the Study of Bioethical Issues, which released the second part of a...
Source: Science - The Huffington Post - March 27, 2015 Category: Science Source Type: news

High-Dose Donepezil: Which Patients Benefit?High-Dose Donepezil: Which Patients Benefit?
Is high-dose donepezil effective for reducing symptoms of Alzheimer disease? Medscape Internal Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 24, 2015 Category: Consumer Health News Tags: Internal Medicine Ask the Expert Source Type: news

Namzaric (Memantine/Donepezil) for the Treatment of Alzheimer's Disease
Namzaric (memantine/donepezil) is the first fixed-dose combination drug approved for the treatment of moderate and severe Alzheimer's disease in the US. (Source: Drug Development Technology)
Source: Drug Development Technology - February 17, 2015 Category: Pharmaceuticals Source Type: news

Donepezil May Slow Hippocampal Atrophy in Prodromal AD Donepezil May Slow Hippocampal Atrophy in Prodromal AD
A new study shows that donepezil slows atrophy of the hippocampus in patients with prodromal Alzheimer's disease, although this did not correlate with cognitive benefit. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - February 4, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Namzaric (Memantine Hydrochloride Extended-release and Donepezil Hydrochloride Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 2, 2015 Category: Drugs & Pharmacology Source Type: news

FDA OKs Namzaric Combo Pill for Alzheimer's DiseaseFDA OKs Namzaric Combo Pill for Alzheimer's Disease
The memantine/donepezil combination offers a once-daily fixed-dose combination of two treatments often prescribed together in one capsule. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 27, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

Actavis and Adamas Announce FDA Approval of Namzaric(TM), a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride
Indicated for Treatment of Moderate to Severe Alzheimer's Disease DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 -- (Healthcare Sales & Marketing Network) -- Actavis plc (ACT) and Adamas Pharmaceuticals Inc. (ADMS) today announced that the U.S. Food and ... Biopharmaceuticals, Neurology, FDAActavis , Adamas Pharmaceuticals, Namzaric, Alzheimer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 24, 2014 Category: Pharmaceuticals Source Type: news

The real-life Limitless pill? Drug helps adults learn as fast as children by making the brain more 'elastic'
Professor Takao Hensch rewired the brain of a visually impaired women to process images using Alzheimer's drug donepezil. (Source: the Mail online | Health)
Source: the Mail online | Health - March 31, 2014 Category: Consumer Health News Source Type: news

The drug that helps adults learn as fast as children
Professor Takao Hensch rewired the brain of a visually impaired women to process images using Alzheimer's drug donepezil. (Source: the Mail online | Health)
Source: the Mail online | Health - March 31, 2014 Category: Consumer Health News Source Type: news

Forest Laboratories submits NDA to FDA for combination drug to treat Alzheimer's disease
US-based Forest Laboratories has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for a fixed-dose combination (FDC) of memantine HCl extended release (ER) and donepezil HCl to treat moderate to severe Alzheimer's t… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 6, 2014 Category: Pharmaceuticals Source Type: news

Forest Files NDA For Alzheimer's Combination Therapy
Forest Laboratories announced it has submitted an NDA to the FDA for the fixed dose combination of memantine HCL extended release and donepezil HCL as treatment for moderate to severe dementia related to Alzheimer’s disease. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - March 5, 2014 Category: Pharmaceuticals Source Type: news

Could vitamin E slow dementia?
Conclusion This was a well-conducted randomised controlled trial with a relatively long follow-up period (average two years). The aim was to see whether adding treatment with either a vitamin E supplement, memantine, or the combination, improved functional ability in people with mild to moderate Alzheimer’s disease. And who were also already receiving treatment with licensed acetylcholinesterase inhibitor drugs. The study found a small though statistically significant difference in the decline of ability to carry out daily tasks in people taking vitamin E compared to placebo. There was also a corresponding ...
Source: NHS News Feed - January 2, 2014 Category: Consumer Health News Tags: Neurology Source Type: news

Dr Reddy's launches Alzheimer's drug in US mkt
Dr Reddy's Laboratories today said it has launched generic Donepezil Hydrochloride tablets, used to treat Alzheimer's disease, in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 27, 2013 Category: Pharmaceuticals Source Type: news

Novel Agent May Boost Aricept Efficacy (CME/CE)
BOSTON (MedPage Today) -- Adding an investigational agent targeting the 5HT-6 serotonin receptor to donepezil (Aricept) boosted cognition scores relative to donepezil alone in a mid-stage trial, a researcher said here. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - July 18, 2013 Category: Consumer Health News Source Type: news

Lu AE58054 as add-on to donepezil
- H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced the presentation of the first clinical data on the investigational drug Lu AE58054 (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 17, 2013 Category: Drugs & Pharmacology Source Type: news

Aricept Helps Cognition in Parkinson's (CME/CE)
SYDNEY (MedPage Today) -- Parkinson's disease patients who have impaired cognition appeared to benefit from the Alzheimer's disease medicine donepezil (Aricept) with no detriment to their motor skills, researchers reported here. (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - June 18, 2013 Category: Psychiatry Source Type: news

Reduced Risk Of Heart Attacks For Patients On Alzheimer's Disease Drugs
Drugs that are used for treating Alzheimer's disease in its early stages are linked to a reduced risk of heart attacks and death, according to a large study of over 7,000 people with Alzheimer's disease in Sweden. The research, which is published online in the European Heart Journal [1], looked at cholinesterase inhibitors (ChEIs), such as donepezil, rivastigmine and galantamine, which are used for treating mild to moderate Alzheimer's disease [2]... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 6, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news